Literature DB >> 17442708

Perlecan--a multifunctional extracellular proteoglycan scaffold.

Mary C Farach-Carson1, Daniel D Carson.   

Abstract

Perlecan is a large multidomain heparan sulfate proteoglycan of the extracellular matrix. Expression of this proteoglycan changes dynamically during embryo implantation and placentation. Perlecan is expressed by various cells of the embryo including trophectoderm and trophoblast as well as the maternal compartment, including basal lamina underlying uterine epithelia and endothelia and, most dynamically, in developing decidua. Perlecan supports various biological functions, including cell adhesion, growth factor binding, and modulation of apoptosis. Moreover, studies in other systems demonstrate that perlecan expression and activity can be controlled at many levels, including transcription, alternative splicing, and extracellular proteolysis. This review will discuss changes in perlecan expression that occur during embryo implantation and placentation. Furthermore, we propose a model in which perlecan represents an extracellular scaffold protein that supports complex, distinct functions in its full-length form or smaller forms generated by alternative mRNA splicing, extracellular proteolysis, or glycosidase action.

Mesh:

Substances:

Year:  2007        PMID: 17442708     DOI: 10.1093/glycob/cwm043

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  66 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

2.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

Review 3.  The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy.

Authors:  Stephen Douglass; Atul Goyal; Renato V Iozzo
Journal:  Connect Tissue Res       Date:  2015-07-16       Impact factor: 3.417

4.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

5.  Interdisciplinary collaborative team for blastocyst implantation research: inception and perspectives.

Authors:  Koji Yoshinaga; Mercy PrabhuDas; Christopher Davies; Kenneth White; Kathleen Caron; Thaddeus Golos; Asgerally Fazleabas; Bibhash Paria; Gil Mor; Soumen Paul; Xiaoqin Ye; Sudhansu K Dey; Thomas Spencer; Robert Michael Roberts
Journal:  Am J Reprod Immunol       Date:  2013-11-29       Impact factor: 3.886

6.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

7.  Synthetic alternatives to Matrigel.

Authors:  Elizabeth A Aisenbrey; William L Murphy
Journal:  Nat Rev Mater       Date:  2020-05-27       Impact factor: 66.308

8.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells.

Authors:  Arivalagan Muthusamy; Carlton R Cooper; Ronald R Gomes
Journal:  BMC Biochem       Date:  2010-11-03       Impact factor: 4.059

Review 10.  The potential role of perlecan domain V as novel therapy in vascular dementia.

Authors:  Aileen Marcelo; Gregory Bix
Journal:  Metab Brain Dis       Date:  2014-06-27       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.